Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Mineralys Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -63.45%, a change of -2.61% year-over-year.
Mineralys Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -23.78%, a change of 31.41% year-over-year.
Mineralys Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -23.91%, a change of 69.06% year-over-year.
Mineralys Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -29.73%, a change of 34.95% year-over-year.
Mineralys Therapeutics, Inc. roe for fiscal 2025 was -23.91%, a change of 69.06% from fiscal 2024.
Mineralys Therapeutics, Inc. roe for fiscal 2024 was -92.97%, a change of -63.16% from fiscal 2023.
Mineralys Therapeutics, Inc. roe for fiscal 2023 was -29.81%, a 152.30% decline from fiscal 2022.
Mineralys Therapeutics, Inc. roe for fiscal 2022 was 57.01%.